Transform the industry with technology to create healthier lives


Driven by technology innovation,
the Health segment focuses on the three major areas of pharmaceutical,
devices and diagnosis, and healthcare services and products.

  • 5.89 RMB billion

    Fosun Pharma’s R&D investment in 2022
  • Over 260

    Pipeline projects on innovation drugs, biosimilars, generic drugs, and consistency evaluation items as of the end of 2022
  • HANSIZHUANG (serplulimab injection)

    The first self-developed biopharmaceutical innovative drug
    The world's first monoclonal antibody drug targeting PD-1 for first-line treatment of extensive stage small cell lung cancer
    Approved for three indications in Chinese Mainland
  • HANQUYOU (trastuzumab injection)

    The first monoclonal antibody biosimilar approved in China and Europe
    The BLA for breast cancer and metastatic gastric cancer indications was accepted by the FDA
    China-developed biosimilar with the most marketing approvals, covering more than 40 countries & regions with a cumulative global shipment volume totaling over 3 million units
  • YI KAI DA (ejilunsai injection)

    The first CAR-T cell therapy product approved for marketing in Chinese Mainland
    Second-line indication approved in Chinese Mainland
    Benefited more than 500 patients in China since its launch
  • Artesunate for injection

    The first generation, Artesun®: recommended by the WHO as the first choice for the treatment of severe malaria, which has treated more than 56 million severe malaria patients worldwide
    The second generation, Argesun®: the world’s first artesunate injectable presented with a single solvent system that received WHO PQ
  • Domestic da Vinci Xi surgical system

    The “thoracic and abdominal endoscopy surgical control system” was approved by NMPA
  • Introduced various devices to new markets

    Soprano Titanium™ was introduced to the North American market following regulatory FDA clearance
    Alma Opus was introduced to international markets outside the United States, including the Chinese market
    Vivo45, Vivo1-2 and Vivo3 ventilators entered the Chinese market, new technologies keeping pace with the world
  • 6,448 beds 1

    In member hospitals
    1 It refers to the number of beds in member hospitals as of the end of June 2023
  • Pharmaceutical Manufacturing
  • Devices & Diagnosis
  • Healthcare Services And Products